| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2000;69:1098-1103
© 2000 The Society of Thoracic Surgeons
a Feiring Heart Clinic, Feiring, The National Hospital, University of Oslo, Oslo, Norway
b Division of Heart and Lung Diseases, The National Hospital, University of Oslo, Oslo, Norway
Address reprint requests to Dr Tjomsland, Feiring Heart Clinic, 2093 Feiring, Norway
e-mail: mrisberg{at}ah.telia.no
Background. Previous studies have reported that mortality and morbidity after transmyocardial laser treatment (TML) mainly occur perioperatively. The present study was designed to evaluate left-ventricular function and identify risk factors for cardiac-related adverse events in this phase.
Methods. Forty-nine patients were studied. The inclusion criteria were angina pectoris Canadian Cardiovascular Society Angina Score (CCSAS) class III and IV refractory to medical therapy and untreatable by coronary artery bypass graft or percutaneous transluminal coronary angioplasty, age less than 75 years, left ventricular ejection fraction greater than or equal to 30%, and myocardial regions with reversible ischemia. Hemodynamic data and cardiac adverse events were registered. The follow-up time was 30 days.
Results. A transient decrease in mean cardiac index (CI) was observed, reaching its minimum immediately after end of the surgical procedure (1.8 ± 0.4, p < 0.01 vs baseline). Two patients (4%) died during the postoperative period (30 days). Seventeen patients (35%) experienced adverse cardiac-related events, where CCSAS class IV, unprotected left main stem stenosis, and diabetes mellitus were identified as risk factors in a multivariate analysis.
Conclusions. A transient impairment of left ventricular function was observed after TML. The morbidity and mortality after TML were almost exclusively cardiac-related, identifying CCSAS class IV, unprotected left main stem stenosis, and diabetes as risk factors.
This article has been cited by other articles:
|
|
 |
|
  C. R. Bridges, K. A. Horvath, W. C. Nugent, D. M. Shahian, C. K. Haan, R. J. Shemin, K. B. Allen, and F. H. Edwards The Society of Thoracic Surgeons practice guideline series: transmyocardial laser revascularization Ann. Thorac. Surg., April 1, 2004; 77(4): 1494 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Guleserian, H. S. Maniar, C. J. Camillo, M. S. Bailey, R. J. Damiano Jr, and M. R. Moon Quality of life and survival after transmyocardial laser revascularization with the holmium:YAG laser Ann. Thorac. Surg., June 1, 2003; 75(6): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Saririan and M. J. Eisenberg Myocardial laser revascularization for the treatment of end-stage coronary artery disease J. Am. Coll. Cardiol., January 15, 2003; 41(2): 173 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Krabatsch, R. Petzina, H. Hausmann, A. Koster, and R. Hetzer Factors influencing results and outcome after transmyocardial laser revascularization Ann. Thorac. Surg., June 1, 2002; 73(6): 1888 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Aaberge, K. Rootwelt, S. Blomhoff, K. Saatvedt, M. Abdelnoor, and K. Forfang Continued symptomatic improvement three to five years after transmyocardial revascularization with co2 laser: A late clinical follow-up of the norwegian randomized trial with transmyocardial revascularization J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1588 - 1593. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
